High-Yield LeukoCore™ Covid-19 Leukopak

LeukoCore™ Covid-19 Human Leukopak biospecimens are collected from donors clinically diagnosed with Covid-19 through IRB-approved apheresis procedures. Each leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs), making it ideal for immune profiling, cytokine analysis, and drug development research related to Covid-19 inflammation and immune dysregulation.

Product Features

• Research Use Only (RUO) human Covid-19 leukopaks
• Clinically confirmed Covid-19 donors
• High cell yield for large-scale studies
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

Donor Metadata

• Verified Covid-19 diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Relevant clinical data including Covid-19 severity (if available)

Applications

• Immune cell characterization in Covid-19
• Therapeutic development and screening
• Cell-based assays and cytokine profiling
• Multi-omics studies including single-cell sequencing

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

Covid-19 Leukopak samples are available fresh or cryopreserved. For international shipping or regulatory documentation, please contact [email protected] to confirm regional compliance and shipping availability.